Upstream swells IPO to $255M as it prepares to join Nasdaq along with CAMP4
Upstream Bio has swollen its IPO to $255 million as the company joins CAMP4 Therapeutics this morning in becoming the latest biotechs to list on the Nasdaq. | Upstream Bio has swollen its IPO to $255 million as the company joins CAMP4 Therapeutics this morning in becoming the latest biotechs to list on the Nasdaq.
Two biotechs set out for the public markets this week, with Upstream Bio raising $255 million for its inflammatory disease ...
The offering will fund testing of a potential rival to Amgen’s Tezpire and is already the sixth for an immune drug developer ...
Cambridge’s Camp4 Therapeutics Inc. and Waltham’s Upstream Bio Inc. will both make their debuts on the public markets Friday.
RNA biotech CAMP4 Therapeutics has marked out plans for a $67 million IPO, with inflammation-focused Upstream Bio pegging its ...
This summary provides a snapshot of current health news, including IPO pricing by biotech startups, Sanofi's potential sale of its consumer health business, HMI Medical's acquisition in Singapore, a ...
The gross proceeds to Upstream from the initial public offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $255.0 million. Registration ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback